Biopharmaceutical companies are now riding the wave for extensive Single Use Technology (SUT) integration to design flexible facility layouts. With the implementation of these SUTs, the optimization of downstream processing workflows will continue to accelerate over the next 3 years.
While upstream processing has led to increasing yields, downstream processing has remained a costly bottleneck: advances in titers over the past two-decade shift the main manufacturing costs from USP towards DSP. There is a lot space for improvement in DSP by leveraging process intensification techniques that allow replacing multi-use steps with high regulatory burden by single use solutions.
3M has put together several platforms relating to each other in unique ways which stand to revolutionize bio-pharmaceutical manufacturing.